Onkure Therapeutics (NASDAQ: OKUR) insider transactions
In the twelve months to 10 November 2026, executives and directors of Onkure Therapeutics reported 8 open-market sales of 1,554 shares ($5,634) and 0 open-market purchases, by 2 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 21 September 2026 | Saccomano Nicholas A | President and CEO | Open-market sale | −87 | $2.97 | 11,160 | Form 4 |
| 21 September 2026 | Leverone Jason A. | Chief Financial Officer | Open-market sale | −302 | $2.97 | 18,500 | Form 4 |
| 22 June 2026 | Saccomano Nicholas A | President and CEO | Open-market sale | −86 | $4.40 | 11,247 | Form 4 |
| 22 June 2026 | Leverone Jason A. | Chief Financial Officer | Open-market sale | −303 | $4.40 | 18,802 | Form 4 |
| 23 March 2026 | Saccomano Nicholas A | President and CEO | Open-market sale | −86 | $4.16 | 7,333 | Form 4 |
| 23 March 2026 | Leverone Jason A. | Chief Financial Officer | Open-market sale | −301 | $4.16 | 16,000 | Form 4 |
| 31 December 2025 | Mathers Edward T | Director | Grant or award | +3,911 | — | 15,310 | Form 4 |
| 31 December 2025 | Manke Isaac | Director | Grant or award | +5,258 | — | 20,583 | Form 4 |
| 22 December 2025 | Saccomano Nicholas A | President and CEO | Open-market sale | −87 | $2.97 | 7,419 | Form 4 |
| 22 December 2025 | Leverone Jason A. | Chief Financial Officer | Open-market sale | −302 | $2.97 | 16,301 | Form 4 |
| 30 September 2025 | Mathers Edward T | Director | Grant or award | +4,125 | — | 11,399 | Form 4 |
| 30 September 2025 | Manke Isaac | Director | Grant or award | +5,545 | — | 15,325 | Form 4 |
| 22 September 2025 | Saccomano Nicholas A | President and CEO | Open-market sale | −88 | $2.62 | 3,506 | Form 4 |
| 22 September 2025 | Leverone Jason A. | Chief Financial Officer | Open-market sale | −303 | $2.62 | 12,603 | Form 4 |
| 30 June 2025 | Mathers Edward T | Director | Grant or award | +4,694 | — | 7,274 | Form 4 |
| 30 June 2025 | Manke Isaac | Director | Grant or award | +6,311 | — | 9,780 | Form 4 |
| 23 June 2025 | Leverone Jason A. | Chief Financial Officer | Open-market sale | −303 | $2.38 | 12,906 | Form 4 |
| 23 June 2025 | Saccomano Nicholas A | President and CEO | Open-market sale | −88 | $2.38 | 3,594 | Form 4 |
| 15 May 2025 | Cormorant Private Healthcare Fund III LP | — | Open-market sale | −1,813,439 | $1.85 | 0 | Form 4 |
| 15 May 2025 | Acorn Capital Advisors Gp, Llc | — | Open-market purchase | +270,270 | $1.85 | 1,709,944 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Onkure Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.